ELRIG and The Protein Society announce keynote speakers for Protein Sciences in Drug Discovery 2026
Programme to focus on AI, machine learning and data-driven approaches across protein design, characterisation and therapeutic development
9 Oct 2026
ELRIG and The Protein Society has announced the keynote speakers for Protein Sciences in Drug Discovery 2026. Prof. Dame Carol Robinson DBE FRS FMedSci FRSC, Director of the Kavli Institute for Nanoscience Discovery at the University of Oxford; Dr. Andrew Doré, Head of Structural Biology at Isomorphic Labs; and Prof. Paula Booth, Daniell Chair of Chemistry at King’s College London (KCL), will lead this year’s conference taking place at GSK Stevenage, UK, from November 10–11, 2026.
The free-to attend event offers scientists from academia, pharma, biotech and CROs the opportunity to explore emerging developments in protein science and their application to modern drug discovery.
The program will explore AI and machine learning in protein science; challenging targets and complexes; antibody and alternative biologic developability and quality control; and the production challenges associated with non-standard binding proteins.
There will be valuable networking opportunities to exchange ideas, build new connections and explore potential collaborations, alongside meeting technology and service providers through the exhibition. Early Career Professionals will also be eligible for the poster award recognising the research that the next generation of scientists bring to drug discovery.
Prof. Dame Carol Robinson has held the University of Oxford Chair of Dr Lee’s Professor of Chemistry since 2009. She is the first Director of the Kavli Institute for Nanoscience Discovery at Oxford and the first female Professor of Chemistry at the Universities of Oxford and Cambridge.
She is recognized for establishing mass spectrometry as a viable technology to study the structure, function and interactions of proteins and their complexes. In 2016, she founded OMass Technologies, now OMass Therapeutics, which uses high-definition native mass spectrometry to develop drug therapies for immunologic and genetic disorders.
Dr. Andrew Doré is Head of Structural Biology at Isomorphic Labs. He earned his DPhil at the University of Cambridge and was a postdoc at the Institute of Cancer Research. He later founded and led Structural Biology at Heptares Therapeutics (Sosei Heptares / Nxera).
He subsequently served as Vice President at CHARM Therapeutics, pairing 3D deep learning with structural biology for oncology. At Isomorphic, his team is applying AI to enable the rational design of next-generation precision medicine of high therapeutic value.
Prof. Paula Booth holds the Daniell Chair of Chemistry at KCL, and leads a Satellite Group at the Francis Crick Institute. Previously, as Head of Chemistry at KCL, she led the renaissance of the department and is now the inaugural Co-Director of King's new Centre for Physical Science of Life.
Prof. Booth has pioneered approaches at the interface of chemistry and biology to probe the biosynthetic folding of integral membrane proteins, studying reaction mechanisms, regulation by membrane lipids and constructing biomembranes for synthetic biology applications.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
Who are the keynote speakers for Protein Sciences in Drug Discovery 2026?
The keynote speakers are Prof. Dame Carol Robinson of the University of Oxford’s Kavli Institute for Nanoscience Discovery, Dr. Andrew Doré of Isomorphic Labs, and Prof. Paula Booth of King’s College London.
When and where is Protein Sciences in Drug Discovery 2026 taking place?
The free-to-attend conference will take place at GSK Stevenage, UK, from November 10–11, 2026. It will bring together scientists from academia, pharma, biotech and contract research organizations.
What topics will Protein Sciences in Drug Discovery 2026 cover?
The program will cover AI and machine learning in protein science, challenging targets and complexes, antibody and alternative biologic developability, quality control, and production challenges involving non-standard binding proteins. It will also offer networking, an exhibition and an Early Career Professionals poster award.